KORU Medical Systems, Inc. (KRMD) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. KORU Medical Systems, Inc. develops, manufactures, and commercializes large volume subcutaneous infusion solutions, primarily for the delivery of immunoglobulin to treat Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company operates as a single segment with revenue streams from domestic core, international core, and pharma services/clinical trials.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $11,764,624 | $9,635,075 |
| Gross Profit | $7,231,389 | $6,046,335 |
| Gross Margin | 61.5% | 62.8% |
| Net Operating Loss | $(864,923) | $(1,245,005) |
| Net Loss | $(807,078) | $(1,166,237) |
| Net Loss Per Share (Basic & Diluted) | $(0.02) | $(0.03) |
| Cash and Cash Equivalents | $8,767,774 | $8,735,834 |
| Net Cash from Operating Activities | $14,663 | $(237,467) |
| Total Debt (Lease Liabilities) | $3,365,725 | $3,496,252 |
Note: The company has a $10 million credit facility ($5M revolver, $5M term loan) with no outstanding borrowings as of March 31, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 22.1% year-over-year. Domestic core revenue grew 11.7%, while international core revenue surged 35.2% driven by pre-filled syringe conversions in the EU. Pharma services and clinical trials revenue jumped 166.0%.
- Profitability: The net loss narrowed by 30.8% to $0.81 million, primarily due to a $1.2 million increase in gross profit, partially offset by an $0.8 million increase in operating expenses.
- Margins: Gross margin decreased 130 basis points to 61.5%, attributed to higher production costs and tariff-related charges not present in the prior year.
- Cash Flow: The company generated positive operating cash flow of $14,663, a significant improvement from the $237,467 outflow in Q1 2025.
- Inventory: Inventory increased by $0.8 million to $4.5 million to meet expected future demand.
Guidance, Outlook, and Management Commentary
- Executive Transition: CEO Linda Tharby announced her retirement, effective June 30, 2026, transitioning to a non-executive advisory role. As part of the separation, 380,000 unvested restricted stock awards were forfeited in Q1 2026, with additional forfeitures expected upon her transition.
- Liquidity: Management expects cash on hand and operating cash flows to be sufficient for at least the next twelve months. The company has not drawn on its credit facility.
- Tariffs: The company imports materials subject to U.S. tariffs. While a federal court ordered refunds for certain tariffs in February 2026, the company has not recorded any benefit due to uncertainty regarding amounts and timing.
- Debt Amendment: On March 30, 2026, the company amended its credit facility to extend maturities (revolver to 2028, term loan to 2029), extend the interest-only period, and lower the interest rate floor to 5.50%.
Investor Verification Checklist
- CEO Transition Plan: Verify the timeline and impact of the CEO's departure on strategic execution and leadership stability.
- Tariff Refund Realization: Monitor the actual receipt of tariff refunds and their potential impact on future gross margins.
- Pharma Services Sustainability: Assess whether the 166% growth in pharma services is recurring or driven by one-time clinical trial milestones.
- Inventory Levels: Track inventory turnover to ensure the $0.8 million increase aligns with actual sales velocity and does not lead to write-downs.
- Stock-Based Compensation: Review the impact of the CEO's stock forfeiture on future compensation expenses and equity dilution.